Dimensional Fund Advisors LP Trims Stake in Becton, Dickinson and Company $BDX

Dimensional Fund Advisors LP cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.6% during the 1st quarter, Holdings Channel.com reports. The firm owned 2,271,757 shares of the medical instruments supplier’s stock after selling 133,673 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Becton, Dickinson and Company were worth $357,139,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. Pacific Capital Partners Ltd lifted its position in shares of Becton, Dickinson and Company by 28.2% in the fourth quarter. Pacific Capital Partners Ltd now owns 37,500 shares of the medical instruments supplier’s stock valued at $7,278,000 after acquiring an additional 8,250 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Becton, Dickinson and Company by 4.4% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock worth $122,403,000 after acquiring an additional 26,671 shares during the period. Cooke & Bieler LP grew its position in shares of Becton, Dickinson and Company by 27.2% during the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock worth $218,614,000 after purchasing an additional 240,673 shares in the last quarter. Finally, Generate Investment Management Ltd purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth about $12,615,000. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Piper Sandler lowered their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Zacks Research raised shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $180.29.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $153.68 on Wednesday. The company has a market cap of $42.35 billion, a price-to-earnings ratio of 38.91, a PEG ratio of 10.93 and a beta of 0.21. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock’s 50 day simple moving average is $149.34 and its two-hundred day simple moving average is $165.61. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 5,188 shares of company stock worth $765,120. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.